Oppenheimer Reaffirms Their Buy Rating on KemPharm

By Austin Angelo

Oppenheimer analyst Derek Archila reiterated a Buy rating on KemPharm (NASDAQ: KMPH) yesterday and set a price target of $13. The company’s shares closed yesterday at $3.55.

Archila wrote:

“KMPH provided several pipeline updates including the announcement of a new pipeline program, KP484, a super-extended release methylphenidate which could provide a benefit on ADHD symptoms potentially for >16 hours. While the KP484 program seems interesting, it is too early stage for us to include in our valuation at this time. On KP415, the company remains on track to deliver pharmacokinetic (PK) data as early as late this year or early 2018. We are positive on the company’s continued prioritization of its ADHD assets, particularly given the CEO’s prior development experience in this indication with Vyvanse.”

According to TipRanks.com, Archila is ranked 0 out of 5 stars with an average return of -8.8% and a 29.6% success rate. Archila covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, Zynerba Pharmaceuticals, and Endo International.

Currently, the analyst consensus on KemPharm is Strong Buy and the average price target is $9.67, representing a 172.4% upside.

In a report released yesterday, Roth Capital also initiated coverage with a Buy rating on the stock with a $8 price target.

The company has a one year high of $5.50 and a one year low of $2.90. Currently, KemPharm has an average volume of 5,055.

Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of KMPH in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. Its portfolio of product addresses pain, attention-deficit or hyperactivity disorder, and central nervous system. The company was founded by Christal M. M. Mickle and Travis C.